GlassScriptPhysician profile
Melissa G Winn
NPI 1053341495
$786.63
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $167 · 2020: $252 · 2021: $314 · 2022: $13.63 · 2023: $39.59.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $39.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $39.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $222.08 | 2019-2023 | Liletta |
| Coopersurgical, INC. | $84.95 | 2020-2021 | |
| Exeltis, USA INC. | $74.90 | 2020-2021 | |
| Allergan, INC. | $68.18 | 2019-2020 | |
| Hologic Sales and Service, LLC | $47.93 | 2019-2020 | |
| Lupin INC. | $40.53 | 2020 | |
| Evofem Biosciences, INC. | $35.83 | 2021 | |
| Pfizer INC. | $34.16 | 2020-2023 | |
| Agile Therapeutics, INC. | $30.57 | 2021-2022 | |
| Therapeuticsmd, INC. | $29.81 | 2020-2021 | |
| Astellas Pharma US INC | $22.36 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.22 | 2019 | |
| Merck Sharp & Dohme LLC | $18.18 | 2019 | |
| Mylan Pharmaceuticals INC. | $16.50 | 2019 | |
| Vertical Pharmaceuticals, LLC | $15.51 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $12.48 | 2019 | |
| Minerva Surgical, INC | $11.44 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Winn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.